**Author details**

Erika Orta‐Salazar<sup>1</sup> , Isaac Vargas‐Rodríguez<sup>1</sup> , Susana A Castro‐Chavira<sup>1</sup> , Alfredo I. Feria‐Velasco<sup>2</sup> and Sofía Díaz‐Cintra1\*

\*Address all correspondence to: yodi@unam.mx

1 Institute of Neurobiology (INB), Developmental Neurobiology and Neurophysiology UNAM‐JuriquillaQuerétaro, México

2 Laboratory of Cellular Neurobiology, Department of Cellular and Molecular Biology, CUCBA, University of Guadalajara Zapopan Jalisco, México

## **References**


[10] De Strooper B, Karran E. Review. The cellular phase of Alzheimer's disease, Cell. 2016;164:603–615. DOI:10.1016/j.cell.2015.12.056.

**Author details**

210 Update on Dementia

Erika Orta‐Salazar<sup>1</sup>

**References**

3465‐6.

Alfredo I. Feria‐Velasco<sup>2</sup>

, Isaac Vargas‐Rodríguez<sup>1</sup>

CUCBA, University of Guadalajara Zapopan Jalisco, México

\*Address all correspondence to: yodi@unam.mx

781. DOI:10.1126/science.1132814.

World Health Organization.

DOI:978 92 4 156445 8.

Med. 2012;2(8). DOI: 10.1101/cshperspect.a006239.

over the path to follow? Ageing Res Rev. 2016; 25: 70–84.

Exp Rev Neurother. 2014;14: 621–630.

UNAM‐JuriquillaQuerétaro, México

and Sofía Díaz‐Cintra1\*

1 Institute of Neurobiology (INB), Developmental Neurobiology and Neurophysiology

2 Laboratory of Cellular Neurobiology, Department of Cellular and Molecular Biology,

[1] Wolkow CA, Zou SM, Mattson P. Aging of the Nervous System, In: Wolf N S, editor. The Comparative Biology of Aging, Springer, 2010: p. 319–352. DOI:10.1007/978‐90‐481‐

[2] Goedert M, Spillantini MG. A century of Alzheimer's disease, Science. 2006;314:777–

[3] Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect

[4] Suzman J, Beard RE. 2011. Global Health and Aging. National Institute on Aging, National Institutes of Health, U.S. Department of Health and Human Services, and

[5] World Health Organization, Dementia: a public health priority, Dementia. 2012; 112.

[6] Dzamba D, Harantova L, Butenko O, Anderova M. Glial cells—the key elements of Alzheimer's disease, Curr Alzheimer Res. 2016; 13 (8): 894–911. [Epub ahead of print]

[7] Choonara YE. Pillay V, du Toit L C, Modi G, Naidoo D, Ndesendo VM, Sibambo SR. Trends in the molecular pathogenesis and clinical therapeutics of common neurode‐ generative disorders. Int J Mol Sci. 2009; 2510–2557. DOI:10.3390/ijms10062510.

[8] Amtul Z. Why therapies for Alzheimer's disease do not work: do we have consensus

[9] Zetterberg H, Mattsson N. Understanding the cause of sporadic Alzheimer's disease

, Susana A Castro‐Chavira<sup>1</sup>

,


[36] Lazarov O, Robinson J, Tang YP, Hairston IS, Korade‐Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 2005;120:701–713. DOI:10.1016/j.cell. 2005.01.015.

[23] Selkoe DG. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–

[24] Price JC, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's Disease. Ann Neurol. 1999;45: 358–368. DOI:10.1002/1531‐8249(199903)45.

[25] Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:

[26] Erten‐Lyons D, Dodge HH, Woltjer R, Silbert LC, Howieson DB; Kramer P, Kaye JA., Neuropathological basis of age‐associated brain atrophy, JAMA Neurol. 2013;70:616–

[27] Delatour M, Guégan M, Volk A, Dhenain M. In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice. Neurobiol Aging. 2006;27:835–847.

[28] Gonzalez‐Lima F, Berndt JD, Valla JE, Games D, Reiman EM. Reduced corpus callosum, fornix and hippocampus in PDAPP transgenic mouse model of Alzheimer's disease.

[29] Redwine JM, Kosofsky B, Jacobs RE, Games D, Reilly JF, Morrison JH, Young WG, Bloom FE. Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc Natl Acad Sci

[30] Valla J, Schneider LE, Gonzalez‐Lima M, Reiman EM. Nonprogressive transgene‐ related callosal and hippocampal changes in PDAPP mice. Neuroreport. 2006;17:29–

[31] Yin J, Turner GH, Coons SW, Maalouf M, Reiman EM, Association of amyloid burden, brain atrophy and memory deficits in aged apolipoprotein ε4 mice. Curr Alzheimer

[32] Norden DM, Muccigrosso MM, Godbout JP. Neuropharmacology microglial priming and enhanced reactivity to secondary insult in aging, and traumatic CNS injury, and neurodegenerative disease. Neuropharmacology. 2015;96:29–41. DOI:10.1016/j.neuro‐

[33] Witcher KG, Eiferman DS, Godbout JP. Priming the inflammatory pump of the CNS after traumatic brain injury. Trends Neurosci. 2015;38:609–620. DOI:10.1016/j.tins.

[34] Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C, Manalastas A, Hilfiker M, Pfister S, Schwerdel C, Riether C, Meyer U, Knuesel I. Systemic immune challenges trigger and drive Alzheimer‐like neuropathology in mice. J Neuroinflammation.

[35] Mhatre SD, Tsai CA, Rubin AJ, James ML, Andreasson KI. Microglial malfunction: the third rail in the development of Alzheimer's disease. Trends Neurosci. 2015;38:621–636.

766.

212 Update on Dementia

32.

631–639. DOI:10.1038/nature02621.

622. DOI:10.1001/jamaneurol.2013.1957.

Neuroreport. 2001;12(11):2375–2379.

Res. 2014;11:283–290. DOI:PMID: 24694076.

2012;9:1‐23. DOI: 10.1186/1742‐2094‐9‐151.

USA. 2002;100(3): 1381‐1386.

pharm.2014.10.028.

2015.08.002.


subdomains and is modulated by PSD‐95 and PSD‐93. J Neurosci. 2010;30:8162–8170. DOI:10.1523/JNEUROSCI.1792‐10.2010.


[60] Sterniczuk R, Antle MC, Laferla FM, Dyck RH. Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 2. Behavioral and cognitive changes. Brain Res. 2010; 1348:149–55. DOI: 10.1016/j.brainres.2010.06.011.

subdomains and is modulated by PSD‐95 and PSD‐93. J Neurosci. 2010;30:8162–8170.

[49] Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl. 1998;53:127‐40. Review. PubMed PMID: 9700651.

[50] Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogen‐

[51] Recuero M, Serrano E, Bullido MJ, Valdivieso F. Abeta production as consequence of cellular death of a human neuroblastoma overexpressing APP. FEBS Lett. 2004;570:114–

[52] Schmitt, HP. epsilon‐Glycation, APP and Abeta in ageing and Alzheimer disease: a hypothesis. Med Hypotheses. 2006;66:898–906. DOI:10.1016/j.mehy.2005.11.016. [53] Rosenkranz SC, Geissen M, Härter K, Szalay B, Ferrer I, Vogel J, Smith S, Glatzel M. Amyloid‐precursor‐protein‐lowering small molecules for disease modifying therapy of Alzheimer's disease. PLoS One. 2013;18:8(12):e82255. DOI:10.1371/journal.pone.

[54] Zahs KH. Ashe KH, "Too much good news" – are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci. 2010;33:381–

[55] Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson‐ Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid‐ b attenuates Alzheimer‐ disease‐like

[56] Awasthi M, Singh S, Pandey VP, Dwivedi UN. Alzheimer's disease: an overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products. J Neurol Sci. 2016;361:256–

[57] Foley JA, Cocchini G, Logie RH, Della Sala S. No dual‐task practice effect in Alzheimer's

[58] Westerman MA, Cooper‐Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002;22(5):

[59] Lok K, Zhao H, Zhang C, He N, Shen H, Wang Z, Zhao W, Yin M. Effects of accelerated senescence on learning and memory, locomotion and anxiety‐like behavior in APP/PS1 mouse model of Alzheimer's disease. J Neurol Sci. 2013;335:145–154. DOI:10.1016/j.jns.

pathology in the PDAPP mouse. Nature. 1999;400:173–177.

esis of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1994;57: 419–425.

DOI:10.1523/JNEUROSCI.1792‐10.2010.

118. DOI:10.1016/j.febslet.2004.06.025.

389. DOI:10.1016/j.tins.2010.05.004.

271. DOI:10.1016/j.jns.2016.01.008.

disease. Memory 2015;23(4): 518–528.

0082255.

214 Update on Dementia

1858‐1867.

2013.09.018.


oxide production: a link between genetic risk and oxidative stress. Neurobiol Aging. 2002;23:777–785. DOI:10.1016/S0197‐4580(02)00016‐7.


progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25(4):402‐405. Erratum in: Nat Genet. 2000;26(1):127.

[83] Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2007;293(5534) 91–103. DOI: 10.1111/j.1750‐3639.2007.00051.x.

oxide production: a link between genetic risk and oxidative stress. Neurobiol Aging.

[71] Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta. 2005;1739(2‐3):240‐250. Review DOI:10.1016/j.bbadis.2004.08.007. [72] Gómez‐Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's

[73] Kril JJ, Patel S, Harding AJ, Halliday GM. Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta

[74] Kondo J, Honda T, Mori H, Hamada Y, Miura R, Ogawara M, Ihara Y. The carboxyl third of tau is tightly bound to paired helical filaments. Neuron. 1988; 1(9):827–834.

[75] Braak H, Braak E. Neuropathological stageing of Alzheimer‐related changes. Acta

[76] Braak H, Braak E. Frequency of stages of Alzheimer‐related lesions in different age

[77] Mena R, Edwards PC, Harrington CR, Mukaetova‐Ladinska EB, Wischik CM. Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. Acta Neuropathol. 1996;91: 633–641. DOI:10.1007/s004010050477.

[78] Mena R and Luna‐Muñoz J. Stages of pathological tau‐protein processing in Alzheim‐ er's disease: from soluble aggregations to polymerization into insoluble tau‐PHFs, in: R.B. Maccioni, G. Perry (Eds.), Current Hypotheses and Research Milestones in

[79] Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Haesendonck C, Borghgraef P, Van Leuven F. Changed conformation of mutant Tau‐P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau‐4R/2N transgenic mice.

[80] Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. Enhanced neurofi‐ brillary degeneration in transgenic mice expressing mutant tau and APP. Science.

[81] Higuchi M, Ishihara T, Zhang B, Hong M, Andreadis A, Trojanowski J, Lee VM. Transgenic mouse model of tauopathies with glial pathology and nervous system

[82] Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn‐Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and

categories. Neurobiol Aging. 1997;18(4):351‐357. PubMed PMID:9330961.

Alzheimer's Disease. 2005: p. 247. DOI: 10.1007/978‐0‐387‐87995‐6.

J Biol Chem. 2005;280:3963–3973. DOI:10.1074/jbc.M409876200.

2002;293(5534):1487‐1491. DOI:10.1126/science.1062097.

degeneration. Neuron. 2002;35:433–446.

Neuropathol. 2002; 103(4):370–376. DOI:10.1007/s00401‐001‐0477‐5.

2002;23:777–785. DOI:10.1016/S0197‐4580(02)00016‐7.

disease. Ann Neurol. 1997;41:17–24. PMID: 9005861.

DOI:10.1016/0896‐6273(88)90130‐4.

216 Update on Dementia

Neuropathol. 1991;82(4): 239–259.


against advanced late‐onset and incipient early‐onset cases. J Neural Transm Park Dis Dement Sect. 1991;3:1–14.


transgenic Alzheimer's disease mice. CNS Neurosci Ther. 2016;22(1): 63–73. DOI: 10.1111/cns.12473.

[107] Luchsinger JA, Noble JM, Scarmeas N. Diet and Alzheimer's disease. Curr Neurol Neurosci Rep. 2007;7(5):366‐372.

against advanced late‐onset and incipient early‐onset cases. J Neural Transm Park Dis

[95] Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM. Impaired insulin and insulin‐like growth factor expression and signaling mechanisms in Alzheimer's disease—is this type 3 diabetes? J Alzheimers Dis. 2005;

[96] Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin‐like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine, J Alzheimers Dis.

[97] Grieb P, Intracerebroventricular streptozotocin injections as a model of Alzheimer's disease: in search of a relevant mechanism. Mol. Neurobiol. 2016;53(3)1–12. DOI:

[98] Wu Z, Yu J, Zhu A, Nakanishi H. Nutrients, microglia aging, and brain aging. Oxid

[99] Fang EF, Scheibye‐Knudsen M, Chua KF, Mattson MP, Croteau DL, Bohr VA. Nuclear DNA damage signalling to mitochondria in ageing. Nat Rev Mol Cell Biol. 2016;17(5):

[100] Grimm A, Friedland K, Eckert A. Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer's disease, Biogerontology. 2016;17(2):1–16.

[101] Swerdlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta ‐ Mol. Basis Dis.

[102] Toglia P, Cheung KH, Mak DD, Ullah G. Impaired mitochondrial function due to familial Alzheimer's disease‐causing presenilins mutants via Ca(2+) disruptions. Cell

[103] Xie H, Hou S, Jiang J, Sekutowicz M, Kelly J, Bacskai BJ. Rapid cell death is preceded by amyloid plaque‐mediated oxidative stress. Proc Natl Acad Sci USA. 2013;110(19):

[104] Cassano T, Pace L, Bedse G, Lavecchia AM, De Marco F, Gaetani S, Serviddio G. Glutamate and Mitochondria: two prominent players in the oxidative stress‐induced

[105] Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci USA.

[106] Chen YJ, Zheng HY, Huang XX, Han SX, Zhang DS, Ni JZ, He XY. Neuroprotective effects of icariin on brain metabolism, mitochondrial functions, and cognition in triple‐

Med Cell Longev. 2016:7498528. DOI:10.1155/2016/7498528.

2014;1842:1219–1231. DOI:10.1016/j.bbadis.2013.09.010.

neurodegeneration. Curr Alzheimer Res. 2016;13:185–197.

2010;107:18670–18675. DOI:10.1073/pnas.1006586107.

Dement Sect. 1991;3:1–14.

10.1007/s12035‐015‐9132‐3

308‐321. DOI:10.1038/nrm.2016.14.

Calcium. DOI:10.1016/j.ceca.2016.02.013.

7904‐7909. DOI:10.1073/pnas.1217938110.

7:63–80.

218 Update on Dementia

2005;8:247–68.


[130] Brunk UT, Terman A. Lipofuscin: mechanisms of age‐related accumulation and influence on cell function, Free Radic Biol Med. 2002;33: 611–619. DOI:10.1016/S0891‐ 5849(02)00959‐0.

[118] Bedi KS. Spatial learning ability of rats undernourished during early postnatal life.

[119] Cintra L, Díaz‐Cintra S, Galván A, Kemper T, Effects of protein undernutrition on the dentate gyrus in rats of three age groups. Brain Res. 1990;532:271–277. PMID:

[120] Levitsky DA, Strupp BJ. Malnutrition and the brain: changing concepts, changing

[121] Almeida SS, Tonkiss J, Galler JR. Prenatal protein malnutrition affects avoidance but not escape behavior in the elevated T‐maze test. Physiol Behav. 1996;60: 191–195. DOI:

[122] Castro‐Chavira AS, Aguilar‐Vázquez AR, Martínez‐Chávez Y, Palma L, Padilla‐Gómez E, Diaz‐Cintra S. Effects of chronic malnourishment and aging on the ultrastructure of pyramidal cells of the dorsal hippocampus. Nutr Neurosci. 2015;1–8. DOI:

[123] Wiley CD, Velarde MC, Lecot, Liu S, Sarnoski EA, Freund A, Shirakawa K, Lim HW, Davis SS, Ramanathan A, Gerencser AA, Verdin E, Campisi J. Mitochondrial dysfunc‐ tion induces senescence with a distinct secretory phenotype. Cell Metab. 2015;23(2):

[124] Gray DA, Woulfe J. Lipofuscin and aging: a matter of toxic waste. Sci Aging Knowl

[125] Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta. 2010;1802: 2–

[126] Georgakopoulou EA(1), Tsimaratou K, Evangelou K, Fernandez Marcos PJ, Zoum‐ pourlis V, Trougakos IP, Kletsas D, Bartek J, Serrano M, Gorgoulis VG. Specific lipofuscin staining as a novel biomarker to detect replicative and stress‐induced senescence. A method applicable in cryo‐preserved and archival tissues. Aging (Albany

[127] Merlo S, Nakayama AB, Brusco J, Rossi MA, Carlotti CG Jr, Moreira JE. Lipofuscin granules in the epileptic human temporal neocortex with age. Ultrastruct Pathol.

[128] Giaccone G, Orsi L, Cupidi C, Tagliavini F. Lipofuscin hypothesis of Alzheim‐ er's disease. Dement Geriatr Cogn Dis Extra. 2012;1: 292–296. DOI:10.1159/000329544.

[129] Seong SY, Matzinger P. Hydrophobicity: an ancient damage‐associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004; 4: 469–478.

Physiol. Behav. 1992;51: 1001–1007.

concerns. J Nutr. 1995;125: 2212S–2220S.

10.1016/0031‐9384(95)02209‐0.

10.1179/1476830515Y.0000000009.

303‐314. DOI: 10.1016/j.cmet.2015.11.011

10. DOI:10.1016/j.bbadis.2009.10.006.

NY). 2013;5: 37–50.

DOI:10.1038/nri1372.

Environ. 2005;5: re1. DOI:10.1126/sageke.2005.5.re1.

2015;39:378–384. DOI:10.3109/01913123.2015.1043416.

2282520.

220 Update on Dementia


[155] Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Van‐ dersteen A, Segers‐Nolten I, Van Der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D'Hooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B. Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J. 2010. 29: 3408–3420. DOI:10.1038/emboj.2010.211.

[142] Vicente R, Mausset‐Bonnefont AL, Jorgensen C, Louis‐Plence P, Brondello JM. Cellular senescence impact on immune cell fate and function. Aging Cell. DOI: 10.1111/acel.

[143] Streit WJ, Xue QS. Alzheimer's disease, neuroprotection, and CNS immunosenescence.

[144] von Bernhardi R, Eugenín‐von Bernhardi, Eugenín J. Microglial cell dysregulation in brain aging and neurodegeneration, Front Aging Neurosci. 2015;7:124. DOI:10.3389/

[145] Ke HC, Huang HJ, Liang KC, Hsieh‐Li HM. Selective improvement of cognitive function in adult and aged APP/PS1 transgenic mice by continuous non‐shock treadmill

[146] Morgan T. Wong A. Finch C. Anti‐inflammatory mechanisms of dietary restriction in slowing aging processes, in: N.Y. Mobbs C.V. (New York (Ed.), Mech. Diet. Restrict.

[147] Ke HC, Huang HJ, Liang KC, Hsieh‐Li HM. Selective improvement of cognitive function in adult and aged APP/PS1 transgenic mice by continuous non‐shock treadmill

[148] Golde TE, Miller VM. Proteinopathy‐induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. Alzheimers Res

[149] Wisniewski HM, Moretz RC, Lossinsky AS. Evidence for induction of localized amyloid deposits and neuritic plaques by an infectious agent. Ann Neurol. 1981;10:517–

[150] Honma T, Hatta K, Hitomi Y, Kambayashi Y, Hibino Y, Konoshita T, Nakamura H. Increased systemic inflammatory interleukin‐1 and interleukin‐6 during agitation as predictors of Alzheimer's disease. Int J Geriatr Psychiatry. 2013;28:233–241. DOI:

[151] Wisniewski T, Ghiso J, Frangione B. Alzheimer's disease and soluble A beta. Neurobiol

[152] Devi L, Ohno M. Cognitive benefits of memantine in Alzheimer's 5XFAD model mice decline during advanced disease stages. Pharmacol Biochem Behav. 2016;144: 60–66.

[153] Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297: 353–356. DOI:10.1126/science.

[154] Nilsson P, Saito T, Saido TC. New mouse model of Alzheimer's. ACS Chem Neurosci.

Aging. 1994;15:143–52. DOI:10.1016/0197‐4580(94)90105‐8.

exercise. Brain Res. 2011;1403:1–11. DOI: 10.1016/j.brainres.2011.05.056

exercise. Brain Res. 2011;1403:1‐11. DOI: 10.1016/j.brainres.2011.05.056.

Front Pharmacol. 2012;3 138. DOI:10.3389/fphar.2012.00138.

Aging Dis. 2007: pp. 83–97. DOI:10.1159/000096557.

Ther. 2009;1(2): 5. DOI:10.1186/alzrt5.

522. DOI:10.1002/ana.410100605.

DOI:10.1016/j.pbb.2016.03.002.

2014;5: 499–502. DOI:10.1021/cn500105p.

10.1002/gps.3816.

1072994.

12455.

222 Update on Dementia

fnagi.2015.00124.

